Alirocumab Labeling Updated With Dosing for HeFH Patients Undergoing LDL Apheresis
The dosing recommendation was based on data from a double-blind, placebo-controlled study conducted in 62 patients with HeFH undergoing LDL apheresis.
All articles by Diana Ernst, RPh
FDA: Cancer Treatment ‘Alternative’ May Cause Serious Heart Problems, Death
Cesium chloride is not approved by the FDA to treat cancer or any other disease.
Heart Meds Recalled After Discovery of Possible Carcinogenic Impurity
As valsartan is used to treat various cardiovascular conditions including heart failure and hypertension, patients should continue to take their medications until they have a replacement product,
Hydralazine-Induced Hepatotoxicity Described in Case Report
Symptoms in patients with short latency include fever, rash, and eosinophilia.
Gastroprotective Effects of PPIs, H2RAs Compared in Patients on Clopidogrel
For this study, researchers searched several large databases (from 1980 to 2016) for randomized, controlled trials (RCTs) that compared clinical outcomes in patients on DAPT taking PPIs or H2RAs.
Hyperkalemia Treatment Lokelma Gets FDA Approval
Lokelma is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium.
FDA: Clarithromycin May Increase Cardiovascular Risks in Existing Heart Disease
The FDA recommends that healthcare professionals should be cautious when prescribing clarithromycin to patients with heart disease.
Aliskiren Oral Pellets Now Approved for Treatment of Pediatric Hypertension
The FDA has approved aliskiren oral pellets for hypertension treatment.
FDA Safety Alert: Biotin Interferes With Cardiac Troponin Results
FDA releases safety alert that biotin can significantly interfere with certain lab tests and cause incorrect results which may go undetected.
Acute Pancreatitis Linked to Diuretic in Coronary Artery Disease
Furosemide-induced acute pancreatitis can occur several hours to up to 7 weeks after starting treatment.
- Loading...
Loading...
Next post in CHD
Loading... 
Loading...